Arthur Bassot

Glioblastoma (GBM) is an aggressive and lethal malignant brain tumor with a median survival of approximately 18 months after diagnosis. GBMs display extensive cellular and molecular heterogeneity, which critically contributes to poor patient outcomes. The metabolic adaptive programs employed by highly plastic and aggressive GBM subtypes in response to their microenvironment are key drivers of disease progression and relapse. Therefore, targeting this metabolic flexibility is essential for effective GBM treatment. In this study, we screened eight well-characterized metabolic drugs targeting GBM metabolism across multiple paired patient-derived differentiated (GDC) and stem cell (GSC) cell lines, identifying R-sodium-lipoate (R-LA) as the most potent and broadly effective inhibitor of GBM aggressiveness and cell-death inducer. Kinomic profiling under R-LA treatment revealed a broad inhibitory effect on kinase activities, while Seahorse analyses, functional tracing and metabolomic studies demonstrated significant modulation of GBM cell metabolism. Finally, R-LA-treatment significantly prolonged survival in GBM-bearing mice, highlighting its therapeutic potential as a metabolic-targeting drug in GBM management.

Despite the wealth of data generated in the omics era to investigate molecular drivers, glioblastoma (GBM) remains one of the most incurable cancers with a poor median of survival. Here we unravelled the dynamic crosstalk between the endoplasmic reticulum and mitochondria, known as mitochondria-associated membranes (MAMs) and define how modulation of calcium fluxes and MAM structure influences GBM cell plasticity and metabolic flexibility. We identified ERO1α, whose expression is significantly associated with poor GBM patient survival, as a critical MAM protein that regulates MAM structure, dynamics and calcium-mediated functions. Our data demonstrate that ERO1α activity and expression promotes GBM aggressiveness in vitro and in vivo and enhances mitochondrial oxidative phosphorylation. By establishing a direct link between ERO1α-mediated MAM modulation and the antitumour effects of ERO1α inhibition, this work highlights a context-dependent, druggable vulnerability that can be exploited for GBM therapy.

Le réticulum endoplasmique et la mitochondrie sont deux organites majeurs impliqués dans la régulation du métabolisme glucido-lipidique. Ces structures interagissent au niveau de points de contact étroits appelés Mitochondria-Associated Endoplasmique Reticulum Membranes (MAMs). Les MAMs sont une zone de communication et d’échanges, de lipides et de calcium entre autre, indispensables à l’activité des deux organites et au maintien de l’homéostasie cellulaire. Des connexions physiques sont assurées par l’interaction de protéines complémentaires, comme le canal anionique voltage-dépendant (VDAC)-1, la protéine chaperonne (Grp)-75 et le récepteur de l'inositol 1,4,5-triphosphate (IP3R)-1, constituant un complexe impliqué dans le transfert de calcium. D’autres acteurs comme les mitofusines 1 et 2 (MFN1/2) assurent également un rapprochement entre les deux organites et semblent jouer un rôle dans les échanges des lipides. Récemment, les MAMs sont apparues comme un nouveau carrefour de la signalisation de l’insuline dans le foie. Le monoxyde d’azote (NO) participe également au contrôle de la réponse à l’insuline hépatique et a une action spécifique sur la mitochondrie. Mes travaux de thèse ont montré que le NO à des concentrations physiologiques module les interactions entre le RE et la mitochondrie dans le foie et que son action sur les MAMs implique la voie de signalisation sGC/cGMP/PKG. J’ai également démontré que la modulation des MAMs par le NO semble jouer un rôle clé dans la régulation de la voie de signalisation à l’insuline (projet1). Par ailleurs, j’ai exploré l’importance des MAMs dans la régulation du métabolisme lipidique. Pour cela, j’ai modulé l’expression protéique de Grp75 et Mfn2 sur un modèle d’hépatocarcinome humain (Huh7). Mes résultats ont montré qu’une surexpression des deux protéines améliore les MAMs et la β-oxydation mitochondriale mais conduit à une accumulation intracellulaire de lipides. Ceci serait dû à un défaut de sécrétion des lipides dans les lipoprotéines VLDL et pourrait impliquer l’apparition d’un stress mitochondrial et une altération des échanges de phospholipides entre les deux organites (projet 2). Par conséquence mon travail confirme le rôle physiologique des MAMs et éclaire les mécanismes d’actions de cette plateforme cellulaire dans la régulation du métabolisme glucido-lipidique hépatique. A plus long terme ces connaissances participeront peut-être à l’identification de potentielles cibles thérapeutiques afin de prévenir la stéatose et la résistance à l’insuline hépatiques et leurs complications

Interactions between mitochondria and the endoplasmic reticulum, known as MAMs, are altered in the liver in obesity, which contributes to disruption of the insulin signaling pathway. In addition, the plasma level of glycine is decreased in obesity, and the decrease is strongly correlated with the severity of insulin resistance. Certain nutrients have been shown to regulate MAMs; therefore, we tested whether glycine supplementation could reduce insulin resistance in the liver by promoting MAM integrity. Glycine (5 mM) supported MAM integrity and insulin response in primary rat hepatocytes cultured under control and lipotoxic (palmitate 500 µM) conditions for 18 h. In contrast, in C57 BL/6 JOlaHsd mice (male, 6 weeks old) fed a high-fat, high-sucrose diet (HFHS) for 16 weeks, glycine supplementation (300 mg/kg) in drinking water during the last 6 weeks (HFHS-Gly) did not reverse the deleterious impact of HFHS-feeding on liver MAM integrity. In addition, glycine supplementation worsened fasting glycemia and glycemic response to intraperitoneal pyruvate injection compared to HFHS. The adverse impact of glycine supplementation on hepatic gluconeogenesis was further supported by the higher oxaloacetate/acetyl-CoA ratio in the liver in HFHS-Gly compared to HFHS. Although glycine improves MAM integrity and insulin signaling in the hepatocyte in vitro, no beneficial effect was found on the overall metabolic profile of HFHS-Gly-fed mice.

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease for which there is currently no cure. Progress in the characterization of other neurodegenerative mechanisms has shifted the spotlight onto an intracellular structure called mitochondria-endoplasmic reticulum (ER) contacts (MERCs) whose ER portion can be biochemically isolated as mitochondria-associated membranes (MAMs). Within the central nervous system (CNS), these structures control the metabolic output of mitochondria and keep sources of oxidative stress in check via autophagy. The most relevant MERC controllers in the ALS pathogenesis are vesicle-associated membrane protein-associated protein B (VAPB), a mitochondria-ER tether, and the ubiquitin-specific chaperone valosin containing protein (VCP). These two systems cooperate to maintain mitochondrial energy output and prevent oxidative stress. In ALS, mutant VAPB and VCP take a central position in the pathology through MERC dysfunction that ultimately alters or compromises mitochondrial bioenergetics. Intriguingly, both proteins are targets themselves of other ALS mutant proteins, including C9orf72, FUS, or TDP-43. Thus, a new picture emerges, where different triggers cause MERC dysfunction in ALS, subsequently leading to well-known pathological changes including endoplasmic reticulum (ER) stress, inflammation, and motor neuron death.

Cells must adjust their redox state to an ever-changing environment that could otherwise result in compromised homeostasis. An obvious way to adapt to changing redox conditions depends on cysteine post-translational modifications (PTMs) to adapt conformation, localization, interactions and catalytic activation of proteins. Such PTMs should occur preferentially in the proximity of oxidative stress sources. A particular concentration of these sources is found near membranes where the endoplasmic reticulum (ER) and the mitochondria interact on domains called MERCs (Mitochondria-Endoplasmic Reticulum Contacts). Here, fine inter-organelle communication controls metabolic homeostasis. MERCs achieve this goal through fluxes of Ca²⁺ ions and inter-organellar lipid exchange. Reactive oxygen species (ROS) that cause PTMs of mitochondria-associated membrane (MAM) proteins determine these intertwined MERC functions. Chronic changes of the pattern of these PTMs not only control physiological processes such as the circadian clock but could also lead to or worsen many human disorders such as cancer and neurodegenerative diseases.

Under physiological conditions, nitric oxide (NO) produced by the endothelial NO synthase (eNOS) upregulates hepatic insulin sensitivity. Recently, contact sites between the endoplasmic reticulum and mitochondria named mitochondria-associated membranes (MAMs) emerged as a crucial hub for insulin signaling in the liver. As mitochondria are targets of NO, we explored whether NO regulates hepatic insulin sensitivity by targeting MAMs. In Huh7 cells, primary rat hepatocytes and mouse livers, enhancing NO concentration increased MAMs, whereas inhibiting eNOS decreased them. In vitro, those effects were prevented by inhibiting protein kinase G (PKG) and mimicked by activating soluble guanylate cyclase (sGC) and PKG. In agreement with the regulation of MAMs, increasing NO concentration improved insulin signaling, both in vitro and in vivo, while eNOS inhibition disrupted this response. Finally, inhibition of insulin signaling by wortmannin did not affect the impact of NO on MAMs, while experimental MAM disruption, using either targeted silencing of cyclophilin D or the overexpression of the organelle spacer fetal and adult testis-expressed 1 (FATE-1), significantly blunted the effects of NO on both MAMs and insulin response. Therefore, under physiological conditions, NO participates to the regulation of MAM integrity through the sGC/PKG pathway and concomitantly improves hepatic insulin sensitivity. Altogether, our data suggest that the induction of MAMs participate in the impact of NO on hepatocyte insulin response.

Glycine is the proteinogenic amino-acid of lowest molecular weight, harboring a hydrogen atom as a side-chain. In addition to being a building-block for proteins, glycine is also required for multiple metabolic pathways, such as glutathione synthesis and regulation of one-carbon metabolism. Although generally viewed as a non-essential amino-acid, because it can be endogenously synthesized to a certain extent, glycine has also been suggested as a conditionally essential amino acid. In metabolic disorders associated with obesity, type 2 diabetes (T2DM), and non-alcoholic fatty liver disease (NAFLDs), lower circulating glycine levels have been consistently observed, and clinical studies suggest the existence of beneficial effects induced by glycine supplementation. The present review aims at synthesizing the recent advances in glycine metabolism, pinpointing its main metabolic pathways, identifying the causes leading to glycine deficiency—especially in obesity and associated metabolic disorders—and evaluating the potential benefits of increasing glycine availability to curb the progression of obesity and obesity-related metabolic disturbances. This study focuses on the importance of diet, gut microbiota, and liver metabolism in determining glycine availability in obesity and associated metabolic disorders.